US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Guided Therapeutics, Inc.

0.3100

0.0000

Volume:2.00

Turnover:0.63

Market Cap:26.65M

PE:-6.47

High:0.3100

Open:0.3100

Low:0.3100

Close:0.3100

52wk High:0.5400

52wk Low:0.0644

Shares:85.96M

Float Shares:27.93M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0479

EPS(LYR):-0.0372

ROE:43.94%

ROA:-111.85%

PB:-3.67

PE(LYR):-8.32

Loading ...

Overview Company News Filings

Guided Therapeutics Reports LuViva Device Detects Cervical Precancers Missed by Standard Care

Guided Therapeutics Receives Third Payment and New Order from Chinese Distributor

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order With Chinese Distributor

THOMSON REUTERS

Guided Therapeutics Secures $200,000 Initial Order from Yuanshuo Medical Instruments

Director James Michael C Reports Acquisition of Common Shares in Guided Therapeutics Inc

Guided Therapeutics Secures $700K Deal with Chinese Partner for Cervical Cancer Screening Products

Guided Therapeutics Inc. Completes Enrollment for US FDA Clinical Trial of LuViva Cervical Scan Device, Begins Data Analysis

Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial

THOMSON REUTERS

Guided Therapeutics Ships Initial Order to New Chinese Partner, Secures $700K Contract

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GTHP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GTHP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GTHP\",,,,,undefined,":{"symbol":"GTHP","market":"US","secType":"STK","nameCN":"Guided Therapeutics, Inc.","latestPrice":0.31,"timestamp":1770998651197,"preClose":0.31,"halted":0,"volume":2,"delay":15,"changeRate":0,"floatShares":27930093,"shares":85958458,"eps":-0.047891,"marketStatus":"Trading","change":0,"latestTime":"02-13 11:04:11 EST Delay","open":0.31,"high":0.31,"low":0.31,"amount":0.63,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.047891,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.31,"volumeRatio":0.000375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GTHP\",,,,,undefined,":{"symbol":"GTHP","floatShares":27930093,"roa":"-111.85%","roe":"43.94%","lyrEps":-0.037243,"volumeRatio":0.000375,"shares":85958458,"dividePrice":0,"high":0.31,"amplitude":0,"preClose":0.31,"low":0.31,"week52Low":0.0644,"pbRate":"-3.67","psRate":"149.70","week52High":0.54,"institutionHeld":0,"latestPrice":0.31,"eps":-0.047891,"divideRate":0,"volume":2,"delay":15,"ttmEps":-0.047891,"open":0.31,"prevYearClose":0.54,"prevWeekClose":0.3999,"prevMonthClose":0.498,"prevQuarterClose":0.54,"fiveDayClose":0.3999,"twentyDayClose":0.39,"sixtyDayClose":0.201},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GTHP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"GTHP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"GTHP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-13","symbol":"GTHP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-03-28","symbol":"GTHP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-13","symbol":"GTHP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699851600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GTHP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GTHP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GTHP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592091315","title":"Guided Therapeutics Reports LuViva Device Detects Cervical Precancers Missed by Standard Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091315","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091315?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:00","pubTimestamp":1765980041,"startTime":"0","endTime":"0","summary":"Guided Therapeutics Inc. has announced preliminary findings from its FDA pivotal clinical trial evaluating the LuViva Advanced Cervical Scan, a device designed for rapid and painless cervical cancer detection using biophotonic technology. The initial results indicate that the current standard of care misses approximately 25% of early cervical precancer cases among women referred for biopsy following abnormal Pap and/or HPV results. The LuViva device aims to improve detection rates of these cases. The completed study enrolled approximately 480 subjects, with over 420 to be evaluated for efficacy, meeting FDA-reviewed protocol criteria. Final clinical results are expected to be filed with the FDA within the next 30 to 60 days. Results from the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLc3rS18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTHP","BK4082"],"gpt_icon":0},{"id":"2590118705","title":"Guided Therapeutics Receives Third Payment and New Order from Chinese Distributor","url":"https://stock-news.laohu8.com/highlight/detail?id=2590118705","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590118705?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461633,"startTime":"0","endTime":"0","summary":"Guided Therapeutics Inc. announced the receipt of an $88,000 payment from its distribution partner, Hangzhou Dongye Medical Technology Company Ltd . Of this amount, $80,000 represents the third installment of a previously announced $700,000 purchase order, with the remaining $8,000 attributed to a new order for LuViva device components. Four LuViva devices and components are scheduled for shipment this month, bringing the total shipped to seven out of 35 devices expected over the coming months. HDMT is the exclusive gynecology products provider for 42 hospitals in Zhejiang Province, China. In addition, Guided Therapeutics recently entered into an agreement with Yuanshuo Medical Instruments Corporation  for an initial $200,000 purchase of LuViva devices and parts, with YMIC set to distribute the products in Jiangsu province.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8v7Grx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GTHP"],"gpt_icon":0},{"id":"2590118185","title":"Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order With Chinese Distributor","url":"https://stock-news.laohu8.com/highlight/detail?id=2590118185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590118185?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUAC2ZYLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","GTHP"],"gpt_icon":0},{"id":"2584944023","title":"Guided Therapeutics Secures $200,000 Initial Order from Yuanshuo Medical Instruments","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944023","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944023?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:00","pubTimestamp":1763560853,"startTime":"0","endTime":"0","summary":"Guided Therapeutics Inc. has announced the completion of an initial supply agreement with Yuanshuo Medical Instruments Corporation , based in Jiangsu province, China. Under the agreement, YMIC will purchase $200,000 worth of LuViva Advanced Cervical Scan devices and single-use components. Additional orders are anticipated next year as part of a broader supply agreement currently under discussion. This new agreement is in addition to an existing arrangement with Hangzhou Dongye Medical Technology Company, Ltd.  for the supply of 35 devices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 19, 2025, and is solely responsi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL837Vdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GTHP"],"gpt_icon":0},{"id":"2565665564","title":"Director James Michael C Reports Acquisition of Common Shares in Guided Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2565665564","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565665564?lang=en_us&edition=fundamental","pubTime":"2025-09-05 23:51","pubTimestamp":1757087472,"startTime":"0","endTime":"0","summary":"James Michael C, a Director of Guided Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL2ySFMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director James Michael C Reports Acquisition of Common Shares in Guided Therapeutics Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GTHP"],"gpt_icon":0},{"id":"2560346194","title":"Guided Therapeutics Secures $700K Deal with Chinese Partner for Cervical Cancer Screening Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2560346194","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560346194?lang=en_us&edition=fundamental","pubTime":"2025-08-19 21:01","pubTimestamp":1755608484,"startTime":"0","endTime":"0","summary":"Guided Therapeutics Inc. has announced a new contract with Hangzhou Dongye Medical Technology Company, Ltd.  in China. The agreement involves a series of nine payments totaling $700,000 for the LuViva Advanced Cervical Scan components and services. So far, Guided Therapeutics has received $100,000, including a recent $70,000 payment which triggers the shipment of three sets of components to HDMT and the manufacture of four additional sets. Once these are assembled and tested, it will initiate the next payment of $80,000. HDMT, based in Hangzhou City, is the exclusive provider of gynecology products for 42 hospitals, conducting approximately two million cervical cancer screenings annually.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL30NF6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTHP","BK4082"],"gpt_icon":0},{"id":"2559602099","title":"Guided Therapeutics Inc. Completes Enrollment for US FDA Clinical Trial of LuViva Cervical Scan Device, Begins Data Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2559602099","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559602099?lang=en_us&edition=fundamental","pubTime":"2025-08-13 21:02","pubTimestamp":1755090138,"startTime":"0","endTime":"0","summary":"Guided Therapeutics Inc. has announced the completion of patient enrollment for its clinical trial involving the LuViva Advanced Cervical Scan, a device designed for the rapid and painless detection of cervical cancer using patented biophotonic technology. The study, which was conducted across four clinical sites, enrolled approximately 430 patients, meeting the company's primary objective for 2025. The data analysis phase is now underway and includes an external review of biopsy samples, data entry from study case report forms, and statistical analysis as per the study protocol. The company anticipates filing the clinical report with the FDA later this year. The trial reported no adverse events linked to the use of LuViva, supporting its designation as a non-significant risk device by the FDA. Results from the statistical analyses are expected to be presented in the future.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL3qJ50z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTHP","BK4082"],"gpt_icon":0},{"id":"2559602797","title":"Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2559602797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559602797?lang=en_us&edition=fundamental","pubTime":"2025-08-13 21:00","pubTimestamp":1755090003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUABFRDGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTHP","BK4082"],"gpt_icon":0},{"id":"2548892022","title":"Guided Therapeutics Ships Initial Order to New Chinese Partner, Secures $700K Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2548892022","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548892022?lang=en_us&edition=fundamental","pubTime":"2025-07-02 21:00","pubTimestamp":1751461242,"startTime":"0","endTime":"0","summary":"Guided Therapeutics, Inc., the developer of the LuViva Advanced Cervical Scan, has announced a new partnership with Hangzhou Dongye Medical Technology Company, Ltd.  in China. The company recently completed its initial shipment of devices and single-use components to HDMT. This shipment is part of a larger agreement, including a separate $700,000 purchase order established earlier this year. From the June 27th shipment alone, Guided Therapeutics will recognize an additional $117,462 in sales revenue for Q2 2025. The first batch of three devices from the new order has already been manufactured and tested, prompting an expected $70,000 payment from HDMT in July 2025. HDMT, based in Hangzhou City, Zhejiang Province, is the exclusive provider of gynecology products for 42 hospitals conducting around two million cervical cancer screenings annually.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL3ZqmyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GTHP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}